LVW Advisors LLC decreased its position in The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 9.2% in the 2nd quarter, Holdings Channel reports. The fund owned 9,033 shares of the medical device company’s stock after selling 915 shares during the period. LVW Advisors LLC’s holdings in Cooper Companies were worth $643,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. Zions Bancorporation National Association UT bought a new position in Cooper Companies during the first quarter worth $33,000. City Holding Co. acquired a new position in Cooper Companies during the first quarter worth about $34,000. GKV Capital Management Co. Inc. acquired a new position in shares of Cooper Companies in the 1st quarter valued at $40,000. Larson Financial Group LLC boosted its position in shares of Cooper Companies by 1,071.0% in the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 664 shares during the period. Finally, HM Payson & Co. boosted its position in shares of Cooper Companies by 147.4% in the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock valued at $75,000 after purchasing an additional 532 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.
Insider Transactions at Cooper Companies
In other news, COO Daniel G. Mcbride bought 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was acquired at an average cost of $65.04 per share, with a total value of $195,120.00. Following the transaction, the chief operating officer directly owned 63,120 shares of the company’s stock, valued at approximately $4,105,324.80. This represents a 4.99% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Gerard H. Warner III bought 1,450 shares of the business’s stock in a transaction dated Friday, September 5th. The stock was acquired at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares in the company, valued at approximately $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 15,975 shares of company stock worth $1,079,566. Insiders own 1.98% of the company’s stock.
Wall Street Analyst Weigh In
Cooper Companies Stock Up 1.0%
COO stock opened at $67.55 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The stock has a market capitalization of $13.43 billion, a P/E ratio of 33.28, a P/E/G ratio of 1.77 and a beta of 0.97. The business has a 50-day moving average of $70.13 and a 200-day moving average of $74.50. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $111.44.
Cooper Companies (NASDAQ:COO – Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.
Cooper Companies announced that its Board of Directors has approved a stock buyback program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.
Cooper Companies Company Profile
The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.
Featured Articles
- Five stocks we like better than Cooper Companies
- 3 Stocks to Consider Buying in October
- 3 Healthcare Stocks Using AI to Drive Growth
- What is a Secondary Public Offering? What Investors Need to Know
- Get Exposure to Millennials’ Purchasing Power With This ETF
- 3 Small Caps With Big Return Potential
- Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.